TECX logo

TECTONIC THERAPEUTIC INC

TECXNASDAQ
🏆 #3033 by market capEarnings Nov 5US Equity
$20.51▲ $0.00 (+0.02%)
Pre-market · at close
🔔
Track TECX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.0%
7d▲ 2.2%
14d▼ 0.8%
30d▼ 11.8%
ytd▼ 1.6%
1y▲ 16.6%
🏦Market Cap
$401M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$20.47 – $21.34
52-Week Range
$15.52 – $39.53
Volume (shares)
5,272
Avg Volume (shares)
—
Shares Outstanding
19.6M
Next Earnings
2026-11-05

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-4.56
Dividend Yield
—
Dilution (1yr)
+23.9%
TECX logo

TECTONIC THERAPEUTIC INC

TECX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$84M▲ +44.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$60M▲ +1.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
18.3M▲ +23.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$253M▲ +$115M YoY
StockOtter · stockotter.space

About TECTONIC THERAPEUTIC INC

Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
15 analysts
Strong Buy6
Buy8
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.